Skip to content

Healthy human tolerance test on Jiashen tablets

Healthy human tolerance test on Jiashen tablets

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIR-17011889
Enrollment
Unknown
Registered
2017-07-06
Start date
2017-07-25
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chest tightness, asthma, cough, edema, limbs, cold, fatigue caused by Long-term congestive heart failure

Interventions

trial group: Jiashen tablets
control group:placebo

Sponsors

The second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) healthy volunteers, men and women half, aged 18-35 years old, the same batch of subjects should not be younger than 10 years of age; (2) Male subjects weighing no less than 50Kg, female subjects weighing no less than 45Kg, all subjects with body mass index at 19-24 (including the critical value); (3) smuggling, alcohol and drug abuse test qualified, general physical examination and laboratory tests, chest radiograph, ECG and other physical and chemical tests are normal; (4) no history of major diseases, no smoking and alcoholism, women of childbearing age pregnancy test negative and not in lactation; (5) Under the GCP, obtain informed consent and volunteer.

Exclusion criteria

Exclusion criteria: (1) heart and kidney and other important organs have primary disease, history of gastrointestinal disease, metabolic disease history, history of neurological diseases; (2) QTcB extension (male> 450ms, female> 470ms); (3) have a history of drug allergy or allergies; (4) have hypokalemia and long QT family history of TdP risk factors such as family members; (5) patients with mental or physical disabilities; (6) physical examination, biochemistry, hematuria will be conventional and ECG, chest X-ray, ultrasound abnormalities, and clinical significance; (7) hepatitis B test, anti-HCV, HIV antibody test was positive; (8) within 3 months using known to have damage to an organism drugs, nearly 2 weeks had taken any drugs, 4 weeks participated in other clinical trials; (9) have bleeding tendency; (10) menstrual period, gestational age, lactating women and women of childbearing age taking contraceptives; (11) Abnormal vital signs (systolic blood pressure 140mmHg, diastolic blood pressure 90mmHg; heart rate 100bpm); (12) 3 months before the test more than 1 daily smoking or use a considerable amount of nicotine products, during the trial can not quit smoking, smoke test is positive; (13) Drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol or 150 mL of alcohol), or alcohol test positive; (14) Drink plenty of tea, coffee and / or caffeinated beverages (8 cups or more, 1 cup = 250 mL) per day; (15) blood transfusion and blood donation history (blood volume greater than 200mL) in the last 3 months; (16) previous history of drug abuse, drug abuse test (morphine, methamphetamine, ketamine, dimethyl dioxy amphetamine, tetrahydrocannabinol, cocaine) positive; (17) According to the judge's judgment, not into the group (such as frail, etc.).

Design outcomes

Primary

MeasureTime frame
Safety indicators and clinical observation;QT/QTc interval;

Countries

China

Contacts

Public ContactHuang Yuhong

The second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine

hyh101@126.com+86 13012264994

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026